Format

Send to

Choose Destination
Liver Int. 2014 Feb;34 Suppl 1:24-8. doi: 10.1111/liv.12397.

Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.

Author information

1
Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt.

Abstract

Hepatitis C virus (HCV) remains one of the leading causes of morbidity and mortality worldwide. Combined therapy with pegylated interferon (PEG-IFN) and ribavirin is the current standard of care treatment for HCV genotype 4. Two types of PEG-IFN are commercially available. The limited number of trials that were conducted for HCV genotype 4 and the few head to head comparisons make it impossible to know which is the best option? In this article we review all available PEG-IFN trials performed worldwide for HCV genotype 4 since 2004. Unless another molecule is developed as a standalone for the treatment of HCV, PEG-IFN will continue to be a source of debate.

KEYWORDS:

HCV genotype 4; PEG-IFN alfa-2a; PEG-IFN alfa-2b

PMID:
24373075
DOI:
10.1111/liv.12397
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center